Radiofrequency ablation

New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias

Retrieved on: 
Friday, May 19, 2023
Abstract, Cardiac electrophysiology, PURE, Cleveland Clinic, PVI, Atrial fibrillation, Stroke, 3D, OH, New product development, Cardiac muscle, Radiofrequency ablation, EGM, MBA, Ablation, Conductor, Hospital, Heart Rhythm, MD, Physician, Risk, Electrophysiology, Arrhythmia, Cleveland, FDA, Pig, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, Medical device

Across all three studies, researchers compared the efficacy of using unipolar signals to guide procedures to the current standard of using an Ablation Index™.

Key Points: 
  • Across all three studies, researchers compared the efficacy of using unipolar signals to guide procedures to the current standard of using an Ablation Index™.
  • "These studies suggest that the preservation of raw cardiac signal enables the use of unipolar signals to help guide ablations, while improving lesion precision and reducing procedure time."
  • The PURE EP™ engineering enables physicians to access the value of unipolar radiofrequency guidance, established by previous studies.
  • A single gap was left in the linear application of the fifth model due to a misinterpretation of the unipolar EGM during pacing.

BioSig to Highlight New Data from the PURE EP™ Platform at Heart Rhythm 2023

Retrieved on: 
Wednesday, May 3, 2023
Radiofrequency ablation, Cardiac muscle, Conductor, Heart Rhythm, Physician, Heart Rhythm Society, Algorithm, Nautilus, Inc. v. Biosig Instruments, Inc., Radio frequency, PURE, Medical imaging, Cleveland Clinic

Westport, CT, May 03, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it will be presenting data at Heart Rhythm 2023, the Heart Rhythm Society's 44th annual meeting, on May 19-21, 2023, in New Orleans, Louisiana.

Key Points: 
  • Westport, CT, May 03, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it will be presenting data at Heart Rhythm 2023, the Heart Rhythm Society's 44th annual meeting, on May 19-21, 2023, in New Orleans, Louisiana.
  • At the meeting, new clinical data collected by the Company’s PURE EP™ Platform will be highlighted in three posters, presented by leading physicians from Cleveland Clinic.
  • BioSig will also be exhibiting at booth #2045 where the Company’s executive leadership, clinical and commercial teams will share customizable features and algorithms of the PURE EP™ Platform, showcasing intracardiac signal specificity unavailable on any other signal technology platform.
  • Abstract and presentation details follow:
    Abstract: Feasibility of Unipolar Signal Guided Ablation in Creating Contiguous Lines of Conduction Block: A Proof-of-Concept Study
    Abstract: Comparison of Unipolar Electrogram Monitoring during Radiofrequency ablation in Viable and Ablated Myocardium: Loss of the S-component

New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors

Retrieved on: 
Tuesday, March 7, 2023
Pleural cavity, Radiofrequency ablation, Lung cancer, Neoplasm, Mouse, Therapy, Patient, RFA, NSCLC, Food, Society, Immune system, Investment, Immunotherapy, SIR, PEF, Food and Drug Administration, Society of Interventional Radiology, Safety, Interventional radiology, Galvanization, Trial of the century, Food preservation, Medical imaging, PHOENIX

PHOENIX, March 7, 2023 /PRNewswire/ -- New interventional oncology data from Galvanize Therapeutics demonstrate positive pre-clinical and early clinical study results using the Aliya™ Pulsed Electric Field (PEF) system.

Key Points: 
  • PEF treatment significantly reduced malignant tissue, and 95% of the assessed sensitive structures within the PEF treatment zone remained viable and unaffected by the PEF energy.
  • Additionally, PEF increased tertiary lymphoid structure accumulation, indicating potential immunoactivation with PEF.
  • PEF also showed greater suppression of tumor growth and had a synergistic effect in combination with immunotherapy, unlike RFA.
  • "We are making additional investments to expand our Aliya™ clinical research program, including a U.S. clinical study of patients with NSCLC."

Stratus® Medical announces first patient enrolled in important double-blinded, randomized, comparative trial comparing the Nimbus® radiofrequency ablation device to conventional radiofrequency ablation for the treatment of Sacroiliac Joint pain

Retrieved on: 
Thursday, March 2, 2023
Needle, PM, Physiology, Research, Assistant, University, Sacroiliac joint, Patient, Radiofrequency ablation, IRB, Physical medicine and rehabilitation, Pain, COBRA, Associate, SIJ, Division, Partnership, Physician, Pharmaceutical industry, Medical imaging, Nimbus, Rehabilitation, Spine

This IRB-approved study will be the first level I, double-blinded, randomized control trial to compare Nimbus bipolar radiofrequency ablation to conventional radiofrequency ablation at three-month, six-month, 12 month, 18 month, and 24 month endpoints.

Key Points: 
  • This IRB-approved study will be the first level I, double-blinded, randomized control trial to compare Nimbus bipolar radiofrequency ablation to conventional radiofrequency ablation at three-month, six-month, 12 month, 18 month, and 24 month endpoints.
  • The goal of the study is to quantify effectiveness and duration of relief for the popular bipolar application in the sacroiliac joint.
  • Bret Boudousquie, Stratus Medical CEO, offered "We are delighted to support this important investigator-initiated research comparing our highly differentiated and patented Nimbus RF technology to conventional RF needles for the treatment of sacroiliac joint pain.
  • We expect this research will further validate the significant clinical advantages of Nimbus compared to conventional RF needles."

Global Tumor Ablation Market Research 2022 to 2028: Featuring BTG, BVM Medical, Erbe Elektromedizin, Healthtronics and Hologic Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 2, 2023
Health, Oncology, Insurance, National Brain Tumor Society, Boston Scientific, Government, Hospital, Allianz, Traction, Cryoablation, Cancer, Breast cancer, Radio, Patient, BTG, Liver, Prostate cancer, Glioblastoma, Axa, Hologic, Neoplasm, Diabetes, Risk, Death, Zurich Insurance Group, Survival, Lung cancer, Growth, BTG (company), Radiofrequency ablation, Brain, Kidney, Ageing, Medical imaging, Pharmaceutical industry, Marketing

The global tumor ablation market is segmented on the basis on technology, application, and end user.

Key Points: 
  • The global tumor ablation market is segmented on the basis on technology, application, and end user.
  • Based on technology, the market is sub-segmented into radio frequency ablation, microwave ablation, cryoablation, and percutaneous ethanol ablation.
  • The major companies serving the global tumor ablation market are Boston Scientific Corp., BTG plc, BVM Medical Ltd., Erbe Elektromedizin GmbH, Healthtronics, Inc., Hologic Inc., and others.
  • Insights about market determinants that are stimulating the global tumor ablation market.

Biosense Webster, Inc. to Highlight Latest Innovations at AF Symposium 2023 Showcasing Breadth of Cardiac Rhythm Portfolio

Retrieved on: 
Monday, January 23, 2023
Rhea, Safety, VisionMap A3 Digital Mapping System, Multicenter trial, Ventricular fibrillation, Medical Affairs Bureau, Diagnosis, President of the European Union, Atrial fibrillation, Arrhythmia, PFA, Treatment, FDA, Catheter, Catheter ablation, Johnson & Johnson, Physician, RFA, Patient, Clinical trial, PVI, Electrophysiology, Paroxysmal attack, Radiofrequency ablation, Science, Pharmaceutical industry, Medical device, Medical imaging

IRVINE, Calif., Jan. 23, 2023 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that data from five company-sponsored studies, including two late breakers, will be presented at the 28th Annual International AF Symposium in Boston from February 2–4. The studies span innovations in radiofrequency ablation (RFA) and pulsed field ablation (PFA) and are part of Biosense Webster, Inc.'s long-standing commitment to advancing electrophysiology innovation.

Key Points: 
  • The studies span innovations in radiofrequency ablation (RFA) and pulsed field ablation (PFA) and are part of Biosense Webster, Inc.'s long-standing commitment to advancing electrophysiology innovation.
  • "As a long-standing leader in this space, we are committed to harnessing the latest science and technology and working in collaboration with physicians to deliver best-in-class solutions."
  • Data from five Biosense Webster, Inc.-sponsored studies will be presented, spanning key topics in electrophysiology.
  • For more information about Biosense Webster Inc.'s presence at AF Symposium and the conference schedule, please visit https://www.afsymposium.com/2023-program .

Dr. Ameer Ali Joins Physician Partners of America- Dallas, TX

Retrieved on: 
Friday, January 13, 2023
Texas Medical Association, Rehabilitation, Partner, Cell biology, Physician, Rutgers University, Pain, Physical medicine and rehabilitation, Quality of life, Vertebral compression fracture, American Society of Interventional Pain Physicians, Patient, Suite, American Academy, Radiofrequency ablation, Human musculoskeletal system, North American Spine Society, Augmented fifth, Interventional pain management, Medicine, Medical imaging

DALLAS, Jan. 13, 2023 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce that interventional pain management specialist Ameer Ali, M.D., has joined the company's North Dallas, Texas pain management practice. He began seeing patients on January 3 at the office, located at 7515 Greenville Ave, Suite 500, Dallas, TX 75231.

Key Points: 
  • DALLAS, Jan. 13, 2023 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce that interventional pain management specialist Ameer Ali, M.D., has joined the company's North Dallas, Texas pain management practice.
  • He began seeing patients on January 3 at the office, located at 7515 Greenville Ave, Suite 500, Dallas, TX 75231.
  • Dr. Ameer Ali is a warm-hearted, board-certified, specialized Spine Care fellowship trained Interventional Pain Management Physician.
  • Dr. Ali enthusiastically focuses on providing superlative treatment which is of the essence for the appropriate management of these painful conditions.

University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems

Retrieved on: 
Thursday, January 5, 2023
Cancer, Prostate cancer, Pancreatic cancer, Radiation, Pancreas, Lung, NCI, Research, News, Irritation, Brain, Physics, Breast, Lustgarten Foundation for Pancreatic Cancer Research, Division, Prostate, Surgical oncology, University Hospitals Cleveland Medical Center, Bladder cancer, Nausea, Patient, Radiosurgery, 2021 Essex County Council election, Physician, Hair loss, U.S. News & World Report, Case Western Reserve University School of Medicine, Kidney, Fatigue, Hospital, Kidney cancer, Magnetic resonance imaging, Cryotherapy, Financial toxicity, Radiofrequency ablation, National Cancer Institute, Radiation therapy, Doctor of Philosophy, Liver, Spine, Medical imaging, Urology, Medicine

DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers.

Key Points: 
  • UH Seidman Cancer Center is part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.
  • "UH Seidman Cancer Center is at the forefront of clinical excellence and transformative innovation.
  • There was unanimous multi-disciplinary support to bring ViewRay's MRIdian MRI-guided radiotherapy to our center and provide our patients with the latest radiotherapeutic advancements.
  • We aim to continue the advancement of MR-guided adaptive radiotherapy through cutting-edge clinical trials and research to improve patient outcomes.

Interventional Oncology Global Market - Forecast To 2029

Retrieved on: 
Thursday, December 22, 2022
Liver cancer, Johnson & Johnson, Radiofrequency ablation, Patient, Brain, LATAM, Liver, Interventional oncology, Kidney cancer, ASC, Medtronic, Boston Scientific, Kidney, SIRT, TACE, Lung cancer, Asia-Pacific Telecommunity band plan in the 700 MHz band, Prevalence, Electroporation, Therapy, Cancer, TAE, Prostate, Lung, IO, Geography, Incidence, Hospital, Prostate cancer, Medical imaging, Varian, Cryoablation

View original content:https://www.prnewswire.com/news-releases/interventional-oncology-global-...

Key Points: 
  • According to IQ4I analysis, the interventional oncology global market is expected to grow at a high single from 2022 to 2029.
  • Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others.
  • The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes.
  • The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares.

The Worldwide Radiofrequency Ablation Devices for Pain Management Industry is Projected to Reach $1 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 6, 2022
Medical Devices, Health, Radiofrequency ablation, Pain management, Growth, Product life-cycle theory, Pet, Video game

The "Radiofrequency Ablation Devices for Pain Management: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Radiofrequency Ablation Devices for Pain Management: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Radiofrequency Ablation Devices for Pain Management estimated at US$516.6 Million in the year 2020, is projected to reach a revised size of US$1 Billion by 2027, growing at a CAGR of 10% over the analysis period 2020-2027.
  • Disposable Products, one of the segments analyzed in the report, is projected to record a 9.9% CAGR and reach US$475.1 Million by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$205.8 Million by the year 2027 trailing a CAGR of 13.6% over the analysis period 2020 to 2027.